Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CKD-MBD KDIGO guidelines: how difficult is reaching the 'target'?

Mario Cozzolino1

  • 1Department of Health Sciences, Renal Division, San Paolo Hospital, University of Milan, Milan, Italy.

Clinical Kidney Journal
|February 10, 2018
PubMed
Summary

Chronic kidney disease-mineral and bone disorder (CKD-MBD) causes abnormal mineral levels and increases mortality risk. Current treatments for CKD-MBD, like phosphate binders and vitamin D, show limited survival benefits due to incomplete understanding of the disease's molecular pathways.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting LDL Across the Whole Spectrum of Chronic Kidney Disease: From Pathophysiology to Novel Treatments.

Current atherosclerosis reports·2026
Same author

How are developments in the treatment armamentarium of hyperphosphatemia addressing the current therapeutic challenges?

Expert opinion on pharmacotherapy·2026
Same author

Missing Opportunity for Nephroprotective Therapy in Patients With Non-Dialysis CKD Under Stable Nephrology Care.

Kidney international reports·2026
Same author

Beyond traditional roles: vitamin D and erythropoietin as immune modulators in kidney diseases.

Clinical kidney journal·2026
Same author

Mineral, Bone, and Cardiovascular Disorders in CKD: The Case for a New Paradigm.

Kidney medicine·2026
Same author

Hemoadsorption Combined with Hemodialysis (HAHD): a Consensus Statement from an International Expert Panel.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026

Area of Science:

  • Nephrology
  • Endocrinology
  • Molecular Biology

Background:

  • Chronic kidney disease (CKD) is frequently associated with mineral and bone disorder (MBD).
  • CKD-MBD involves dysregulation of serum calcium (Ca), phosphorus (P), and parathyroid hormone (PTH).
  • Mineral metabolism derangements in CKD correlate with increased all-cause and cardiovascular mortality.

Purpose of the Study:

  • To highlight the challenges in managing CKD-MBD.
  • To emphasize the need for a deeper understanding of molecular pathways in CKD-MBD.

Main Methods:

  • Review of existing literature on CKD-MBD pathophysiology and treatment.
  • Analysis of the impact of mineral imbalances on patient outcomes.

Main Results:

Keywords:
CKD-MBDKDIGOsecondary hyperparathyroidism

Related Experiment Videos

  • Patients on haemodialysis often have 1,25-dihydroxyvitamin D (calcitriol) deficiency, exacerbating secondary hyperparathyroidism (SHPT).
  • Established treatments like phosphate binders, vitamin D, and calcimimetics offer limited survival advantages.
  • Incomplete understanding of CKD-MBD molecular mechanisms hinders effective therapeutic strategies.

Conclusions:

  • CKD-MBD is a complex, multifactorial condition requiring further research into its underlying molecular pathways.
  • Addressing P overload and SHPT remains a clinical challenge with current therapeutic options.
  • Enhanced comprehension of molecular processes is crucial for developing improved treatments and improving survival in CKD patients.